Friday, 15 Dec 2017

You are here

No Evidence to Support Use of Gabapentinoids in Low Back Pain

Management of chronic low back pain (CLBP) is often complex, requiring multiple modalities and meds to control pain. An analysis of studies shows that Gabapentinoids, including pregabalin and gabapentin, have little to no benefits but significant risk of adverse effects.  (Citation source https://buff.ly/2warMSU)

In a meta-analysis published in PLOS Medicine, researchers from Canada looked at findings from 8 randomized controlled trials that investigated the use of gabapentinoids in adult CLBP patients.

  • 3 studies comparing gabapentin to placebo, gabapentin showed no significant improvement of pain; 
  • 3 studies comparing pregabalin to other analgesics, pregabalin actually fared worse in pain relief. There were commonly reported adverse events included dizziness, fatigue, confusion, and visual disturbances. Functional and emotional outcomes among patients taking gabapentinoids for CLBP showed no significant improvements.

These highly prescribed agents (pregabalin and gabapentin) have little to offer chronic LBP patients as the existing evidence does not support it, but rather points to greater risks with such therapy. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

AASM Guidelines for Sleep Apnea Testing

A task force from the American Academy of Sleep Medicine (AASM) performed a systematic review of the scientific literature on obstructive sleep apnea and screening tests.

Fibromyalgia Diagnosed by Two Simple Tests

Researchers from the Oregon Health Science Center have reported that fibromyalgia can be distinguished from chronic pain by primary care providers (PCPs) who employ two simple screening tests: BP cuff-evoked pain and a single patient question, and pain induced by pinching the Achilles tendon. 

Opioid Crisis Costs US $500 Billion

Reuters reports that the opioid crisis has cost the United States as much as $504 billion in 2015,  based on a White House economists report released this week. The White House Council of Economic Advisers (CEA) said the toll from the opioid crisis represented 2.8% of gross domestic product that year.

DEA Cracks Down on Illicit Fentanyl

Reuters reports that  U.S. Drug Enforcement Administration (DEA) has declaed it would classify illicit versions of fentanyl at the same level as heroin, allowing criminal prosecution of anyone who possesses, distributes or manufactures illicit versions of the drug.

High Drug Discontinuations and Nonadherence in Fibromyalgia

Compliance and adherence was shown to be quite poor in fibromyalgia (FM) patients, with high rates of drug discontinuation and greater than 60% demonstrated low adherence.